News from ABBVIE A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 24, 2015, 14:00 ET
Jul 24, 2015, 07:53 ET

AbbVie Reports Second-Quarter 2015 Financial Results

 AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2015. "We are pleased with the high level of...

Jul 17, 2015, 08:01 ET

C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy

 C2N Diagnostics and AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted their investigational...

Jul 10, 2015, 07:10 ET

IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe

 Today AbbVie (NYSE: ABBV) announced the European Commission (EC) granted marketing authorization for IMBRUVICA® (ibrutinib) as the...

Jul 07, 2015, 14:50 ET

AbbVie apresenta resultados de estudos para Hidradenite Supurativa, doença inflamatória crônica da pele e ainda sem tratamento disponível

A AbbVie, companhia biofarmacêutica global, anuncia resultados de seus dois estudos clínicos pivotais de Fase III, PIONEER I e PIONEER...

Jul 02, 2015, 08:00 ET

AbbVie to Host Second-Quarter Earnings Conference Call

 AbbVie (NYSE: ABBV) will announce its second-quarter 2015 financial results on Friday, July 24, 2015, before the market opens. AbbVie will...

Jul 01, 2015, 10:30 ET

HUMIRA (Adalimumabe) da AbbVie é aprovado no Brasil para tratamento de Espondiloartrite Axial Não Radiográfica

- Este é o primeiro e único medicamento aprovado para tratamento de espondiloartrite axial não radiográfica severa em...

Jun 29, 2015, 14:47 ET

AbbVie anuncia resultados de Fase 3b de estudo com pacientes crônicos com Hepatite C, Genótipo 1b, e Cirrose Hepática Compensada

- 100 % dos pacientes mantiveram resposta virológica sustentada após 12 semanas de tratamento com VIEKIRA PAK (comprimidos de...

Jun 29, 2015, 07:00 ET

AbbVie's HOLKIRA™ PAK Now Reimbursed in Ontario

- Common Drug Review grants positive recommendation for HOLKIRA PAK - Ontario is the second province in Canada to reimburse HOLKIRA...

Jun 24, 2015, 06:00 ET

AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained...

Jun 18, 2015, 17:01 ET

AbbVie Declares Quarterly Dividend

 The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.51 per share.  The cash dividend is payable...

Jun 12, 2015, 09:00 ET

AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorders

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data from studies of DUOPA® (carbidopa and...

Jun 12, 2015, 02:30 ET

Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced updated results of a Phase 1b study that showed patients with...

Jun 08, 2015, 08:00 ET
AbbVie’s Week of Possibilities shows how #AbbVieGivesBack

AbbVie Mobilizes 3,100 Employees for Week of Service Projects to Transform Schools and Communities Globally

 AbbVie, a global biopharmaceutical company, today launched its second annual Week of Possibilities volunteer program, with 3,100 employees...

Jun 08, 2015, 08:00 ET

AbbVie to Present Data from Studies of the Company's Oncology Pipeline at the 20th European Hematology Association Annual Congress

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data on its investigational hematological malignancy...

Jun 05, 2015, 16:00 ET

AbbVie to Present at Goldman Sachs 36th Annual Global Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015. Bill Chase,...

Jun 04, 2015, 07:00 ET

AbbVie's Research in Immunology to be Featured at the European League Against Rheumatism Annual Congress (EULAR) 2015

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced that data from more than 30 abstracts on HUMIRA® (adalimumab),...

Jun 01, 2015, 12:22 ET

AbbVie to Present at Jefferies 2015 Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the Jefferies 2015 Healthcare Conference on Thursday, June 4, 2015. Richard A. Gonzalez, chairman and...

Jun 01, 2015, 08:00 ET

AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting

AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib...

May 31, 2015, 08:00 ET

AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting

 AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a...